Akathisia and second-generation antipsychotic drugs

@article{Kumar2009AkathisiaAS,
  title={Akathisia and second-generation antipsychotic drugs},
  author={Rajeev Kumar and Perminder Singh Sachdev},
  journal={Current Opinion in Psychiatry},
  year={2009},
  volume={22},
  pages={293–299}
}
Purpose of review Akathisa is one of the most common and distressing neuroleptic-induced extrapyramidal side effects. Although it is well recognized in the context of conventional antipsychotic medications, there have been recent concerns raised by clinicians and researchers that this syndrome is overlooked in relation to second-generation or atypical antipsychotics. This review examines the recent literature relevant to second-generation antipsychotic (SGA)-induced akathisia. Recent findings… Expand
Akathisia and Newer Second‐Generation Antipsychotic Drugs: A Review of Current Evidence
TLDR
Clinicians should consider the risk of akathisia when choosing a treatment option and monitor for akath isia in patients beginning therapy with an SGA or following a dose increase of the SGA, as well as manufacturer websites and product labeling. Expand
Second-Generation Antipsychotics and Extrapyramidal Adverse Effects
TLDR
The incidence and severity of extrapyramidal syndrome differ amongst these antipsychotics, but the fact is that these drugs have not lived up to the expectation regarding their tolerability. Expand
Akathisia: Case Presentation and Review of Newer Treatment Agents
Akathisia is a common and potentially debilitating adverse effect of many psy chotropic agents. To a physician not specifically screening for this phenomenon, symptoms can appear similar toExpand
Antipsychotic-induced akathisia in delirium: A systematic review
TLDR
A systematic review of the medical literature found that some populations, such as patients with cancer or terminally ill patients in palliative care settings taking antipsychotics for the treatment of delirium, could be at higher risk for development of akathisia as a side effect. Expand
[Polypharmacy in schizophrenia].
TLDR
For treatment-resistant cognitive symptoms, cognitive re-mediation seems most promising as no pharmacological add-on strategy has gained convincing evidence so far, and further randomized controlled trials, naturalistic and head-to-head-studies are necessary. Expand
Revisiting Antipsychotic-induced Akathisia: Current Issues and Prospective Challenges
TLDR
Despite the initial promise that second generation antipsychotics would be devoid of akathisia effects, this has not been confirmed and the evidence supporting the most widely used treatments (beta blockers, anticholinergic drugs) is still absent or inconsistent. Expand
The clinical challenges of akathisia
TLDR
Some of the confusion surrounding akathisia, its relationship to other disorders, and differential diagnosis, are addressed, as well as treatment alternatives. Expand
Trazodone for the Treatment of Neuroleptic-Induced Acute Akathisia: A Placebo-Controlled, Double-Blind, Crossover Study
TLDR
It is suggested that Trz's property of serotonin 2A postsynaptic receptor antagonism may be its principal mechanism for the improvement of NIA. Expand
Manage antipsychotic-induced akathisia by making changes to the antipsychotic drug regimen and/or adding anti-akathisia agents
TLDR
Patients should first receive an adjustment in their antipsychotic drug regimen, and if further intervention is needed, propranolol is considered as the first-choice anti-akathisia agent. Expand
The Mechanism of Drug-induced Akathisia
TLDR
A possible mechanism for drug-induced akathisia based on the differential functions of the core and shell portions of the nucleus accumbens is described based on contemporary concepts regarding the mechanisms of compulsion, impulsivity, and depression. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 63 REFERENCES
On the relationship of atypical and low-dose conventional antipsychotics with akathisia in a clinical patient population
TLDR
The results suggest favouring atypical antipsychotic medication in patients who may easily develop akathisia, although the chlorpromazine equivalent doses of conventional antipsychotics were lower than those of the atypicals. Expand
Acute nocturnal akathisia induced by clozapine.
TLDR
Akathisia, a subjective complaint of restlessness accompanied by observed movements of the legs, is one of the most disagreeable extrapyramidal side effects of medications and often causes noncompliance in patients with schizophrenia. Expand
Side effects of atypical antipsychotics: extrapyramidal symptoms and the metabolic syndrome.
TLDR
It is concluded that atypical antipsychotics continue to have notable risks of EPS, particularly akathisia, and that these agents also appear to increase the risk of the metabolic syndrome, though this effect seems most marked with clozapine and olanzapine. Expand
Prevalence and severity of akathisia in patients on clozapine
TLDR
Patients receiving clozapine, like patients receiving standard antipsychotic drugs, should be monitored for akathisia, which is observed to be similar in prevalence and severity in patients treated with clozAPine and those receiving standard neuroleptic antipsychotics. Expand
Extrapyramidal side-effects of antipsychotics in a randomised trial
TLDR
The incidence of treatment-emergent EPS and change in EPS ratings indicated that there are no significant differences between second-generation antipsychotics and perphenazine or between second theses antipsychotic drugs in people with schizophrenia. Expand
Aripiprazole augmentation in treatment-resistant bipolar depression: Early response and development of akathisia
TLDR
The usefulness of aripiprazole in the treatment of bipolar depression may be limited by akathisia, though limited by its small sample size and naturalistic design. Expand
Antipsychotic-Induced Extrapyramidal Side Effects in Bipolar Disorder and Schizophrenia: A Systematic Review
TLDR
Bipolar patients, especially in depression, were more vulnerable to having acute antipsychotic-induced movement disorders than those with schizophrenia. Expand
Anticholinergics for neuroleptic-induced acute akathisia.
TLDR
There is no reliable evidence to support or refute the use of anticholinergic drugs for people suffering from neuroleptic-induced acute akathisia, and the need for well designed, conducted and reported clinical trials to address the claims of open studies is highlighted. Expand
Extrapyramidal side effects with atypical neuroleptics in bipolar disorder
TLDR
Over one-half of bipolar patients experienced EPS in this real world clinical setting, much higher than the 5-15% range reported in clinical trials, suggesting potential problems with clinical trial generalizability. Expand
Role of Mirtazapine in the Treatment of Antipsychotic-Induced Akathisia
TLDR
Mirtazapine may be considered a treatment option for antipsychotic-induced akathisia and may be especially useful for patients with contraindications or intolerability to β-blockers and for those with comorbid depression or negative symptoms. Expand
...
1
2
3
4
5
...